Phase Genomics
PrivateLast Round
Grant
Mar 4, 2024
Total Funding Raised
$21.1M
Company Overview
Phase Genomics is a biotechnology company that develops and sells proximity ligation kits, scientific services, and computational analyses for genomic research.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine
Business Model
B2G
Customer Profile
Services & Consulting, Hardware Sales, Government Contracts, Subscription SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Phase Genomics Comparables
Compare Phase Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arima Genomics | 88% | |
| Edenroc Sciences | 84% | |
| Pacific Biosciences of California, Inc. | 67% |
Phase Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 4, 2024 | ||||
| Grant | Aug 7, 2023 | ||||
| Grant | Jun 9, 2022 | ||||
| Grant | Sep 30, 2020 | ||||
| Grant | Jan 8, 2020 | ||||
Grant | Feb 25, 2019 |
Phase Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| Mount Pleasant Ventures | Series A |
| Pack Ventures | Series A |
| Bill & Melinda Gates Foundation | Grant |
| Washington Research Foundation Capital | Seed |
| Congruent Ventures | Seed |
| Andy Hill Cancer Research Endowment Fund | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 23, 2026
Monthly visitors grew 60% MoM, from 1.9K to 3K.
- May 1, 2025
Monthly visitors increased 32% MoM, reaching 3.7K.
Phase Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Phase Genomics's valuation, stock price, and market status.
Is Phase Genomics a public or private company?
Phase Genomics is a private company.
What is the current stock price of Phase Genomics?
Phase Genomics is a private company with no public stock price. No recent secondary market data is available.
How much is Phase Genomics worth (valuation)?
Valuation information for Phase Genomics is not publicly available.
Can I buy Phase Genomics stock?
Phase Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Phase Genomics's last funding round?
Phase Genomics's most recent funding round was Grant on March 4, 2024.
Who are the main investors in Phase Genomics?
Key investors in Phase Genomics include National Institute of Allergy and Infectious Diseases, Bill & Melinda Gates Foundation, Washington Research Foundation Capital.
Will Phase Genomics IPO soon?
No public IPO plans have been announced for Phase Genomics.
How can I track Phase Genomics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Phase Genomics's secondary market activity and sign up for updates.